°
Special Conference Events & Activities

REGISTRATION
18:00-20:00 Wednesday April 14, Rooms A and B (you can also register during conference hours)

Business Sessions (open to all attendees):
16:05-18:30 Thursday April 15, Room B
8:30-12:30 Monday April 19, Room B

Business Session (restricted to general audience)
15:35-18:00 Sunday April 18, Room B

JOB FAIR & DISCUSSIONS. Meet the Speakers and Company Representatives.
16:00-18:30 Friday April 16
17:00-18:30 Saturday April 17
15:00-18:00 Sunday April 18

18:00-23:00 Gala Dinner Sunday April 18 (provided free of charge to all persons registered; please carry your badge)

(Morning, Thursday April 15, Room A)
7:30-8:20 REGISTRATION
8:20-8:50 Introduction: Boulikas, Teni, President & CEO, Regulon, Inc. and Senior Investigator, Institute of Molecular Medical Sciences, Palo Alto, CA: Prospects of gene therapeutics in molecular medicine" (30 min)

9:00-9:45 Opening Lecture: Garry Nolan, Assistant Professor of Molecular Pharmacology, Stanford University: Evolving novel gene therapeutics" (45 min)

9:55-10:10 COFFEE

Nonviral Gene & Drug Delivery
Chair: Szoka, Francis; Martin, Frank; Rolland, Alain; Graham, Roger; Theeuwes, Felix; Patton, John

Liposomal delivery (In memory of Demetrios Papahadjopoulos; COORGANIZERS: Frank Martin and Bob Debs)
10:10-10:25 * Debs, Bob California Pacific Medical Research Institute, San Francisco, CA: "Systemic Anti-angiogenic Gene Delivery" (20 min)
10:30-10:50 * Szoka, Francis, Professor, University of California at San Francisco, School of Pharmacy, San Francisco, CA (20 min)
11:55-11-15 * Martin, Frank, Alza Corporation, Menlo Park, CA: Clinical pharmacology of intravenously-administered liposomes: challenges for gene therapy applications. (20 min)
11:20-11:35 * Working, Peter, Alza Corporation, Menlo Park, CA (15 min)
12:00-12-20 * Papahadjopoulos-Sternberg, Brigitte, California Pacific Medical Research Institute, San Francisco, CA: "Optimization of cationic liposome-DNA complexes in vivo: correlation between transfection activity and morphology" (20 min)
12:25-12:45 * Graham, Roger, Director, Preclinical Development, Inex Pharmaceuticals Corp., Burnaby, B.C., Canada: "Strategies to Overcome the Critical Barriers Facing a Systemically Administered Cancer Gene Therapy" (25 min)

12:50-13:50 LUNCH

(Afternoon, Thursday April 15, Room A)
Liposomal delivery (continued)
13:50-14:05 * Thierry, Alain, Director, Department of Gene Therapy & Delivery, Biovector Therapeutics, S.A., Labège, France: "Optimization of Lipoplex for in vivo gene transfer: gallenic and efficiency"
14:10- 14:20 * Duzgunes, Nejat, Professor and Chairperson of Microbiology, University of the Pacific, School of Dentistry, San Francisco, CA: Lipoplexes associated with human serum albumin or transferrin: "Enhanced gene delivery to cell lines and macrophages, and resistance to inhibition by serum" (10 min)

Nonviral gene delivery
14:20-14:45 * Rolland, Alain, Vice President, GeneMedicine Inc., The Woodlands, TX: "Controllable non-viral gene therapy" (25 min)
14:45-15:05 * Norman, Jon, Vice President of Research, and Barnhart, Kerry, Research Manager, Vical, San Diego, CA: "DNA tumor antigen vaccines" (20 min)
15:10-15:25 * Dev, Ken Director of Research, Genetronics, Inc., San Diego, CA: "Electroporation-mediated gene, drug and antisense delivery" (20 min)
15:30-15:50 * Unger, Evan, President & Chief, Executive Officer/ and Matsunaga, Terry, Senior Director, New Product Chemistry, ImaRx Pharmaceutical Corp., Tucson, Arizona: "Ultrasound Enhanced Gene Expression and Gene Delivery."
15:55-16:10 * Leong, Kam, The Johns Hopkins University School of Medicine, Baltimore, MD: "Polymeric controlled delivery for gene therapy" (20 min)

16:15-16:35 COFFEE

Protein and Drug Delivery
16:35-16:55 * Patton, John, Founder and Vice President of Research, INHALE, San Carlos, CA: "Systemic delivery of insulin and other macromolecules by inhalation" (20 min)
17:00-17:20 * Theeuwes, Felix Vice President, Research & Development, Alza Corporation, Mountain View CA and Chairman and Chief Scientific Officer, DURECT: "Drug delivery of protein and peptides" (20 min)

Membrane Translocating and Fusogenic Peptides
17:30-17:45 * Lin, Yao-Zhong, Vanderbilt University, Nashville, TN: "Cellular Protein Delivery Mediated by a Membrane-Translocating Peptide" (15 min)
17:50-18:05 * Vignery, Agnes, Yale University School of Medicine, New Haven, CT: Molecular mechanisms of macrophage fusion (15 min)

18:10-18:30 DISCUSSIONS

18:30 END OF SESSIONS

(Morning, Thursday April 15, Room B)
Molecular Medicine
Chair: Norris, James; Amento, Edward; Anders, Fritz; Escher, Alan; Bernard, Hans-Ulrich

Antibacterial Gene Therapy
10:10-10:30 * Norris, James, Vice Chairman, Department of Microbiology and Immunology, Professor of Medicine and Assistant Dean Graduate School, Medical University of South Carolina, Charleston, South Carolina: "Modified phage delivery of antibacterial gene therapy agents" (20 min)

Fibrotic Disease
10: 40-11:00 * Amento, Edward, Director and Chairman, Molecular Medicine Research Institute, Mountain View CA: Therapeutic actions in autoimmune and connective tissue disease" (20 min)
11:10-11:30 * Martin, George Head of Research, Fibrogen, Inc., South. San Francisco, CA:
11:40-12:00 * Breindl, Michael, Professor, San Diego State University, CA: "Far upstream regulatory elements enhance position-independent and tissue-specific activity of type I collagen promoter in transgenic mice" (20 min)

Cancer
12:05-12:25 * Anders, Fritz, Professor, Genetisches Institut der Justus Liebig Universität, Giessen, Germany: "Paragenetic suppressors of suppressor genes as modifiers of oncogene expression" (20 min)
12:30-12:50 * Iversen, Pat, Senior Vice President, Research & Development, AVI Biopharma, Corvallis, Oregon: "Antisense to c-myc" (20 min)
13:00-13:15 * Bernard, Hans-Ulrich, Professor, Institute of Molecular and Cell Biology, Singapore: Human papillomavirus-16 and cervical cancer

13:20-14:20 LUNCH

(Afternoon, Thursday April 15, Room B)
Diabetes & Obesity
14:20-14:40 * Escher, Alan, Assistant Professor, Center for Molecular Biology & Gene therapy, Loma Linda University, CA: "Intramuscular injection of plasmid DNA encoding intracellular or secreted glutamic acid decarboxylase causes decreased insulitis in the non-obese diabetic mouse" (20 min)

Cytomegalovirus
14:50-15:05 * Bogner, Elke, Institute of Virology, Robert-Koch-Str. 17, 35037 Marburg, Germany: "Are the gene products of UL56 and UL89 the human cytomegalovirus (HCMV) terminase?"
15:10-15:25 * Yao, Feng, Instructor of Surgery, Harvard Medical School, Boston, MA: "Tetracycline-inducible viral replication switch: a novel anti-HSV1 viral vector" (15 min).

Huntington's Disease
15:30-15:45 * Tagle, Danilo, National Human Genome Research Institute National Institutes of Health, Bethesda, MD, USA: "Progressive Neurobehavioral and Neuropathological Changes in Full-length cDNA Transgenic Mouse Models for Huntington's Disease" (20 min)

15:45-16:05 COFFEE

Business Session (open to all attendees)
Moderators: Kaspar, Peter; Simmon, Vincent
16:05-16:25 * Simmon, Vincent, President & CEO, Cortex Pharmaceuticals, Inc., Irvine, CA: "AMPA modulation for the treatment of CNS disorders"(20 min)
16:30-16:50 * Kaspar, Peter, Senior Vice President, Roche Molecular Biochemicals, Berkeley, CA: New tools for gene delivery and protein expression" (20 min)
17:00-17:15 * Marquet, Magda, President and COO, Althea Technologies Inc., San Diego, CA: "Tight specification for high grade plasmid DNA" (15 min)

17:20-18:30 BUSINESS DISCUSSIONS

18:30 END OF SESSIONS

"""""""

(Friday April 16, Room A).
Chair: Lundstrom, Kenneth; Jolly, Douglas; Rozenberg, Yanina

Viral Gene Delivery
HSV, Alphavirus, HIV/Lentiviral vectors
8:30-8:50 * Lundstrom, Kenneth, Section Head, f. Hoffmann-La Roche, Basel, Switzerland: "Efficient gene delivery to rat brain with semliki forest virus vectors" (20 min)
9:00-9:20 * Kingsman, Alan, Professor & CEO, Oxford Biomedica LTD., Oxford, UK: "Primate and non-primate lentiviral vectors for gene therapy" (20 min)
9:30-9:50 * Molnar-Kimber, Katherine, Dept. of Surgery, University of Pennsylvania, Philadelphia, PA: Cancer Therapy using Replication Selective Herpes Simplex Virus I Mutants" (20 min)

Retroviral vectors
10:00-10:25 * Jolly, Douglas, Vice President of Scientific Affairs, Chiron Technologies Center for Gene Therapy, San Diego, CA: "Clinical therapy with directly administered retroviral vectors" (25 min)"

10:30-10:50 COFFEE

10:50-11:10 * Rozenberg, Yanina, Group Leader, Gene Therapy Laboratories, University of Southern California, Norris Cancer Center, Los Angeles, CA: "The role of the retroviral env cytoplasmic domain in viral entry: the implications for the gene delivery vehicle design."

AAV & Adenoviral gene delivery
11:20-11:40 * Monahan, John, President & CEO, Avigen, Inc., Alameda, CA: "Gene therapy to treat hemophilia" (20 min)
11:50-12:10 * Cheng, Seng, Senior Director, Gene Transfer Research, Genzyme Corporation, Framingham, MA, USA: "Correction of enzymatic and lysosomal storage defects in Fabry mice by adenovirus-mediated gene transfer"

12:15-113:15 LUNCH

13:15-13:35 * McMenamin, Mary, Department of Human Anatomy and Genetics, University of Oxford, UK: "Immunological and cytotoxic consequences of using adenoviral vectors for gene delivery to the rodent CNS"
13:45-14:05 * Dong, Jianyun, Associate Professor of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC: "Inducting apoptosis of solid cancers with an adenovirus carrying a hybrid FasL gene: a in vivo gene therapy approach" (20 min)
14:15-14:35 * Yeh, Patrice, Rhône-Poulenc Rorer Gencell, Institut Gustave Roussy, Villejuif, France: "Adenovirus vectors for gene therapy" (20 min)

14:45-15:05 COFFEE

15:05-15:20 * Jalanko, Anu, National Public Health Institute, Helsinki, FINLAND: "Adenovirus-mediated gene transfer in Aspartylglucosaminuria mice" (15 min)
Special lectures:
15:25-15:45 * Fitzpatrick, Stephen, President, Biometics, Inc. Waltham, MA: Scale up and facility design for clinical and licensed production (20 min)
15:50:16:10 * Venables, David, Head, Biotechnology, Covance Laboratories, Harrogate, UK: "Design and Implementation of Gene Therapy Vector Biodistribution Studies."
16:20-16:35 * Murakami, Masaaki, Assistant Professor, Institute of Immunological Science, Hokkaido University, Japan: "Persistent and repeated administration of adenovirus vector by adenovirus vector carrying CTLA4IgG" (15 min)

16:40-18:30 JOB FAIR & DISCUSSIONS. Meet the Speakers and Company Representatives.

18:30 END OF SESSIONS

"""""""

(Friday April 16, Room B).
Chair: Hope, Tom; Palù, Giorgio; Nordstrom, Jeff; Huard, Johnny; Yu, John
Clinical trials on cancer
8:30-8:50 * Yu, John, Neurosurgeon, Neurosurgical Institute, Cedars-Sinai Medical Center, University of California at Irvine, Los Angeles, CA: A novel herpes simplex virus mutant is safe and effective against experimental human glioma (20 min)
9:00-9:20 * Palù, Giorgio, Professor and Chairman, Institute of Microbiology, Padova, Italy: "Gene therapy of glioblastoma multiforme via combined expression of suicide and cytokine genes: a pilot study in humans" (20 min)
9:30-9:50 * Yang, Xiao-dong, Senior Scientist, Preclinical Biology, Abgenix, Inc., Fremont, CA: "Potent Anti-tumor Activity of ABX-EGF, A Fully Human Monoclonal Antibody to the Epidermal Growth Factor Receptor"
Special lecture:
10:00-10:20 * Dehlinger, Peter, Partner, Dehlinger & Associates, Intellectual Property Law, and HERON Bioventures LLC, Palo Alto, CA: "Patenting Gene-Therapy Inventions: From Concept to Clinical Trial" (20 min)

10:30-10:50 COFFEE

Gene/Cell therapy
10:50-11:10 * Huard, Johnny, Assistant Professor of Orthopaedic Surgery and Molecular Genetics and Biochemistry, Children's Hospital of Pittsburgh and University of Pittsburgh, PA: Muscle-based tissue engineering for the musculoskeletal system
11:20-11:40 * Arsenijevic, Yvan, Division of Surgical Research and Gene Therapy Center, Lausanne University Medical School (CHUV), Lausanne, Switzerland: "Gene therapy of amyotrophic lateral sclerosis using polymer-encapsulated xenogenic cell lines secreting hCNTF" (20 min)

Prodrug
11:50-12:05 * Degreve, Bart, Graduate Student, Group of Jan Balzarini, Rega Institute, Leuven, Belgium: The superior bystander effect of purine versus pyrimidine nucleoside analogs in combined gene/ chemotherapy for cancer (15 min)

12:10-13:15 LUNCH

Regulatory DNA elements /Vector improvement
13:15-13:35 * Farmer, Andrew, Research Scientist, Clontech, Palo Alto, CA: "Tetracycline-regulated gene expression: Novel plasmid and viral vectors for improved inducibility in clones and heterogenous cell populations" (20 min)
13:45-14:05 * Nordstrom, Jeff, Director of Gene Expression Systems, GeneMedicine, Inc., The Woodlands, TX: "Ligand-Dependent Regulation of Transgene Expression In Vivo" (20 min)
14:15-14:35 * Hope, Tom, Infectious Disease Laboratory, Salk Institute for Biological Studies, La Jolla, CA: "An RNA element which stimulates the expression of transgenes posttranscriptionally in a variety of gene therapy vectors" (20 min)

14:45-15:05 COFFEE

15:05-15:25 * Doyle, Donald, Postdoctoral Fellow, David Corey lab, Howard Hughes Medical Institute, UT Southwestern Medical Center, Dallas, TX: "Turning genes on and off: engineered nuclear hormone receptors and intracellular delivery of peptide nucleic acids" (20 min)
15:30-15:50 * Rossi, Fabio, Postdoctoral Fellow, Helen Blau Group, Dept of Molecular Pharmacology, Stanford, CA: Advances in tetracycline-inducible gene expression (20 min)

16:00-18:30 JOB FAIR & DISCUSSIONS. Meet the Speakers and Company Representatives.

18:30 END OF SESSIONS

ZZZZZZZ

(Saturday April 17, Room A)
Gene Therapy of Cancer
Chair: Chang, Stephen; Rosenblatt, Joseph; Mandl, Christian; Seth, Prem; Wills, Ken

Cancer Immunotherapy
9:00-9:20 * Rabussay, Dietmar, Vice President, Research and Development, Genetronics, Inc., San Diego, CA: "Increased immune response to DNA vaccines upon intracellular delivery by electroporation"
9:30-9:50 * Pericle, Federica, GeneMedicine, Inc., The Woodlands, TX: "Plasmid-based immunotherapy and cancer vaccine approaches" (20 min)
10:00-10:20 * Mandl, Christian, Associate Professor of Virology, Institute of Virology, University of Vienna, Austria: "Infectious RNA as an attenuated live virus vaccine"

10:30-10:50 COFFEE

Hepatic gene therapy
Plenary Lecture
10:50-11:35 * Kay, Mark, Associate Professor of Pediatrics and Genetics, Stanford University: "Hepatic gene therapy for genetic and acquired diseases" (45 min)

p53 gene-based therapy of cancer
11:45-12:05 * Chang, Stephen, Chief Scientific Officer, Canji Inc., San Diego, CA: "p53 gene therapy" (20 min)
12:15-12:35 * Seth, Prem, Medicine Branch, NCI, NIH, Bethesda, MD: "Cancer gene therapy using an adenovirus expressing p53: pre-clinical studies" (20 min)

12:45-13:50 LUNCH

Strategies for gene therapy of cancer
13:50-14:10 * Rodin, Sergei, Associate Professor, Beckman Research Institute of the City of Hope, Duarte, California, USA: "Multiple p53 mutations in tumors: Interplay between their origin and selection" (20 min)
14:20-14:40 * Chiang, Yawen, Senior Director of Oncology, Rhône-Poulenc Rorer Gencell, Hayward, CA : Cancer gene therapy approaches (20 min)
14:50-15:10 * Wills, Ken, Canji Inc. San Diego, CA: "IFN-a in cancer gene therapy" (20 min)
15:20-15:40 * Wang, Min, Project Leader, Cancer, GeneMedicine, Inc., The Woodlands, TX: "Treatment of tumors by expressing anti-angiogenic factors (e.g. endostatin) from plasmids" (20 min)

15:50-16:10 COFFEE

16:10-16:30 * Hermiston, Terry, Scientist and Team Leader, Molecular Virology, Onyx Pharmaceuticals: "Replication
competent oncolytic virus, ONYX-015 for gene delivery"
16:40-16:55 * Ivanov, Sergey, Intramural Research Support Program, National Cancer Institute, Frederick Cancer Research and Development Center, Frederick, MD: "Transmembrane carbonic anhydrases as markers for renal clear cell carcinoma and other malignancies" (15 min)
17:00-17:15 * Kiselev, SL, Group Leader, Institute of Gene Biology, Russian Academy of Sciences, Moscow, Russia: "tag7 and GM-CSF for gene therapy of mouse M3 melanoma" (15 min)

Cancer Immunotherapy
17:20-17-40 * Chirmule, Narendra, Director, Immunology Core, Institute for Human Gene Therapy, University of Pennsylvania, PA: "Role of Fas-FasL interactions in elimination of transduced cells in vivo"

17:45-18:30 JOB FAIR & DISCUSSIONS. Meet the Speakers and Company Representatives.

18:30 END OF SESSIONS

(Saturday April 17, Room B)
Molecular Biology
Chair: James Shen; Sawadogo, Michele; Dynlacht, Brian

Transcription Factors
9:00-9:20 * Shen, C-K James, Director, Institute of Molecular Biology, Academia Sinica, & Professor, University of California at Davis, Nankang, Taipei, Taiwan, Republic of China: "A novel gene expression cassette in erythroid cells" (20 min)
9:30-9:50 * Sun, Xiao-Hong, Associate Professor, New York University Medical Center, New York, USA: T-cell development and leukemogenesis regulated by the basic helix-loop-helix proteins" (20 min)
10:00-10:20 * Ghosh, Gourisankar, Assistant Professor of Chemistry and Biochemistry, University of California, San Diego, La Jolla, CA: "crystal structure of IkBa/NF-kB" (20 min)

10:30-10:50 COFFEE

10:50-11:10 * Sawadogo, Michele, The University of Texas M.D. Anderson Cancer Center, Houston, TX: "Loss of USF function in cancer cells".
11:20-11:40 * Nordeen, Steven, Professor of Pathology, University of Colorado Health Sciences Center, Denver, CO: "The Site of Viral Promoter Integration Differentiates Regulatory Potential by Related Transcription Factors " (20 min)
11:50-12:20 * Parvin, Jeff, Assistant Professor, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA: "The function of BRCA1 protein in transcription." (30 min)
12:30-12:45 * Hurt, Myra, Associate Professor, Director, Program in Medical Sciences, Florida State University, Tallahassee, FL: The transcription factor YY1 and replication-dependent histone gene expression in mammals

12:50-13:50 LUNCH

(Afternoon, Saturday April 17, Room B)
Nuclear Import
13:50-14:10 * Hannink, Mark, Department of Biochemistry, University of Missouri, Columbia, MO: "Nuclear import of the IkBa protein via a novel receptor-independent nuclear import pathway"

Cell cycle control & Apoptosis
14:20-14:40 * Chellappan, Kumar, Assistant. Professor, Columbia University, New York, NY, USA: "Regulation of the Rb-E2F pathway by signaling cascades"

Molecular Evolution
14:50-15:10 * Trifonov, Ed, Professor, The Weizmann Institute of Science, Rehovot, Israel: "Glycine clock: Eubacteria first, Archaea next, Protoctista, Fungi, Planta and Animalia at last" (20 min)

DNA Repair & Recombination
15:20-15:35 * Chang, Yung, Assistant Professor of Microbiology, Arizona State University, Tempe, AZ: "VDJ recombination in inducible SCID cell lines (15 min)

15:40-16:00 COFFEE

Business Session (open to all attendees)
16:00-16:20 * Stemmer, Willem , Co-founder and Vice President of R& D, Maxygen, Inc., Santa Clara, CA (20 min)
16:30-16:50 * Harper, Mary, Vice President of Research and Development, Desmos, Inc., San Diego, CA: Business talk on DESMOS technology and portfolio approach

17:00-18:00 BUSINESS DISCUSSIONS & JOB FAIR. Meet the Speakers and Company Representatives.

Cell cycle control & Apoptosis
18:00-18:30 * Dynlacht, Brian, Harvard University, Cambridge, MA: Cdk2; cyclins; E2F (25 min)

18:30 END OF SESSIONS

(Sunday April 18, Room A)
Gene & Cell Therapy
Chair: Lebkowski, Jane; Harper, Mary; Rosenblatt, Joseph; Malone, Robert; Law, Peter

HIV gene therapy / Emerging anti-HIV technologies
9:00-9:20 * Faust, Emmanuel, Project Director, Lady Davis Institute for Medical Research, SMBD-Jewish General Hospital, McGill University, Montreal, Quebec, Canada: "The final stages of retroviral integration: Human Immunodeficiency Virus type 1 integrase as a novel target for gene therapy in acquired immune deficiency syndrome" (20 min)
9:30-9:50 * Rosenblatt, Joseph, Chief, Hematology Oncology, University of Rochester Cancer Center, Rochester, NY: "Novel Approaches to Stem Cell Directed Gene Therapy for HIV-1" (20 min)

Telomerase
10:00-10:20 * Lebkowski, Jane, Senior Director of Cell and Gene Therapy, GERON Corporation, Menlo Park CA: "hTERT gene transfer increases the life-span of normal primary human cells" (20 min)

10:30-10:50 COFFEE

Cardiovascular / Angiogenesis
10:50-11:10 * Baker, Andy, Bristol Heart Institute, Bristol, UK: "Prevention of vein graft neointima formation in vitro and in vivo by overexpression of protease inhibitors" (20 min)
11:20-11:40 * Noonan, Douglas, Istituto Nazionale per la Ricerca sul Cancro (IST), Genova, Italy: "inhibition of angiogenesis in a matrigel sponge model by interferon producing cells: a gene therapy approach" (20 min)

Cell Therapy
11:50-12:10 * Harper, Mary, Vice President of Research and Development, Desmos, Inc., San Diego, CA: "Expansion of functional pancreatic islets using Laminin-5 technology for treatment of diabetes" (20 min)

12:20-13:20 LUNCH

Gene therapy of hemophilias
13:20-13:40 * Hurwitz, David, Scientific Director, ALG Company, Marlboro, MA: "Ex vivo gene therapy system utilizing bone marrow stromal cells for the treatment of hemophilia A and B" (20 min)

Myoblast transfer/Gene transfer to muscle
13:50-14:15 * Law, Peter Founder, President and Chairman of the Board, Cell Therapy Research Foundation, Memphis, TN: "Myoblast transfer therapy as a platform technology for gene therapy" (25 min)
14:20-14:35 * La Monica, Nicola, IRBM, Pomezia, Italy: "Naked DNA injection and muscle electrostimulation" (15 min)

Pulmonary transfection
14:40-15:00 * Malone, Robert, Gene Medicine Program, University of Maryland at Baltimore, School of Medicine, Baltimore, MD: "Aurintricarboxylic acid (ATA) strongly enhances direct plasmid transfection of respiratory tissues" (20 min)

15:00-18:00 JOB FAIR & DISCUSSIONS. Meet the Speakers and Company Representatives.

15:00-18:00 COFFEE

18:00-23:00 Gala Dinner (provided free of charge to all persons registered; please carry your badge)

(Sunday April 18, Room B)
Antisense, Triplex DNA, & Ribozymes
Chair: Gruenert, Dieter; Van Dyke, Michael; Levin, Art; Johnston, Brian)

Antisense
Plenary lecture
9:00-9:45:00 * Crooke, Stanley Chairman of the Board, Chief Executive Officer, ISIS Pharmaceuticals, Carlsbad Research Center, Carlsbad, CA: Antisense technology: end of beginning. (45 min)
10:00-10:20 * Crooke, Roseanne, ISIS Pharmaceuticals, Carlsbad Research Center, Carlsbad, CA: "Suborgan distribution of antisense oligonucleotides in liver" (20 min)

10:30-10:50 COFFEE

10:50-11:10 * Levin, Art, ISIS: "Detailed evaluation & pharmacokinetics of antisense oligonucleotides" (20 min)
11:20-11:40 * Dean, Nick, ISIS Pharmaceuticals, Carlsbad Research Center, Carlsbad, CA: "Preclinical animal pharmacology of antisense oligonucleotides" (20 min)

Triplex DNA
11:50-12:10 * Van Dyke, Michael, Associate Professor, The University of Texas M. D. Anderson Cancer Center, Houston, TX: "The yeast CDP1 gene encodes a triple-helical DNA-binding protein" (20 min)

12:20-13:20 LUNCH

(Afternoon, Sunday April 18, Room B)
13:20-13:40 * Seidman, Michael, Investigator, National Institute of Aging, NIH, Baltimore, MD: "Targeted Gene Mutagenesis Mediated by Triple Helix Forming Oligonucleotides" (20 min)

Gene Repair & Targeting
Plenary Lecture
13:50-14:35 * Gruenert, Dieter, University of California, San Francisco, CA (45 min)

Ribozymes/Aptamers
14:45-15:00 * Joshi, Sadhna, Associate Professor and Director of HIV Laboratory, University of Toronto, Ontario, Canada: "HIV gene therapy using antisense RNAs and Ribozymes" (15 min)
15:05-15:25 * Johnston, Brian, President & CEO, Somagenics Inc., Mountain View, CA & Stanford University School of Medicine, Stanford, CA: "Potent antisense activity of RNA Padlocks" (20 min)

15:35-18:00 COFFEE

15:35-18:00 Business Session (restricted to general audience)

15:35-18:00 JOB FAIR & DISCUSSIONS. Meet the Speakers and Company Representatives.

POSTERS
Mhashilkar, Abner, Research Scientist, Introgen Therapeutics, Inc., Houston, TX: "Effect of combination therapy with Ad-p53 and cisplatin in models of head and neck cancer.
Huet, Thierry, Senior Research Fellow, Preclinical Oncology Research, RPR Gencell: "Preclinical studies of Ad5CMV-p53 in combination with chemotherapy or ionizing radiation: improvement of conventional anti-cancer therapies"

18:00 END OF SESSIONS

18:00-23:00 Gala Dinner (provided free of charge to all persons registered; please carry your badge)

(Monday April 19, Room A)
Genomics, Arraying, Gene & Drug Discovery
Chair: Bollon, Arthur; Arnold, Lyle; Edwards, Cynthia; Ferre, Francois; Siebert, Paul; Pfahl, Magnus

Genomics
8:30-8:55 * Somogyi, Roland, Director, Neurobiology, Incyte, Palo Alto, CA: "From gene expression to genetic network inference" (25 min)
9:05-9:25 * Stuart, Susan, Senior Director of Cancer Biology, Incyte Pharmaceuticals, Inc., Palo Alto, CA: (20 min)
9:35-9:55 * Bollon, Arthur, Chairman of the Board and CEO, Cytoclonal Pharmaceuticals, Inc. Dallas, TX: "Genomic Integrative Therapeutics" (20 min)

10:05-10:25 COFFEE

10:25-10:45 * Ferre, Francois, Chief Executive Officer, Althea Technologies Inc., San Diego, CA: "Gene Quantification: Applications to the Field of Gene Therapy" (20 min)
10:55-11:15 * Burke, John, Head, Expression and Chip Design, Pangea Systems, Oakland, CA: "Candidate genes for disease from full-length sequence databases" (20 min)

Drug/Gene Discovery
11:25-11:45 * Pfahl, Magnus, President and CEO, MAXIA Pharmaceuticals, Inc., San Diego, CA: "Novel retinoid related molecules for the treatment of cancer and diabetes" (20 min)
11:55-12:15 * Palmer, Michelle, Director, Tropix PE Applied Biosystems Services, Bedford, MA: "Novel functional cell based assays for accelerated drug discovery" (20 min)

12:25-13:30 LUNCH

13:30-14:00 * Seilhamer, Jeff, Vice President, Molecular Biology Research, Incyte, Palo Alto, CA: "Applications of genomics and proteomics in pharmaceutical development" (30 min)
14:10-14:30 * Soderlind, Eskil, Associate Professor, Director Antibody Development, BioInvent Therapeutic AB, Lund, Sweden: "The CDR-implantation library: a unique source of antibody fragments for targeted therapy, drug discovery processes and research tools." (20 min)

Arraying / DNA chips
14:40-15:00 * Siebert, Paul, Scientific Director, Clontech, Palo Alto, CA: "Identification and verification of differentially-expressed genes on cDNA arrays" (20 min)
15:10-15:35 * Arnold, Lyle, VP of Research and Development, INCYTE Microarray Systems, Fremont, CA: DNA microarrays and drug discovery challenge" (25 min)

15:45-16:05 COFFEE

Genomics/Gene Discovery/Small molecules
16:05-16:25 * Edwards, Cynthia, Chief Scientific Officer, Genelabs Technologies Inc., Redwood City, CA: Designing small molecule drugs that bind TF sites in DNA (20 min)
16:35-16:55 * Meyer, Rick, Vice President, Research, Genelabs Technologies Inc., Redwood City, CA: Combinatorial chemistry for selecting the small molecule drugs (20 min)
17:05-17:25 * Larocca, David, Selective Genetics, San Diego, CA: "Ligand identification via expression LIVE" (20 min)
17:35-17:55 * Zhu, Li, Director, Molecular Biology, Clontech, Palo Alto, CA: "Two-Hybrid System/Human genome protein linkage mapping" (20 min)
18:05-18:25 * Shepard, Michael, Chief Scientific Officer, Newbiotics, Inc., San Diego, CA: "Tumor Suppressor Gene Therapy with Small Molecules" (20 min)

18:30 END OF SESSIONS

(Monday April 19, Room B)
Business Session
Moderators: Abbot, Bob; Rabussay, Dietmar; Hurwitz, David
8:30-8:50 * Titomirov, Alex, President/ CEO, Informax, Inc., North Bethesda, MD: Drug design
9:00-9:20 * Livak, Kenneth, Principal Scientist, PE Applied Biosystems, Foster City, CA: " DNA/RNA Real-Time Quantitative PCR " (20 min)
9:30-9:50 * Travis, Jeff, Vice President of Business Development & Marketing Manager, Arcturus Engineering, Inc., Mountain View, CA: "Laser capture microdissection (LCM): a new and unique tool for rapid specific cell "molecular and biochemical diagnostics" (20 min)

10:00-10:20 COFFEE

10:20-10-50 * Abbot, Bob, CEO, Selective Genetics, San Diego, CA: "Technology & Business Development of Selective Genetics" (30 min)
11:00-11:20 * Hurwitz, David, Scientific Director, ALG Company, Marlboro, MA: "ALG Company: Development of the Ex Vivo Bone Marrow Stromal Cell Gene Therapy System" (20 min)
11:30-11:50 * Hooper, Herbert, Chief Technology Officer, ACLARA Biosciences Inc., Hayward, CA:
12:00-12:20 * Swartzman, Elana, Staff Scientist for PCR Chemistry, PE Applied Biosystems, Foster City, CA: "Using Fluorometric Microvolume Assay Technology (FMAT) for Lead Identification and Characterization in High Throughput Drug Screening " (20 min)

12:30-13:30 LUNCH

(Afternoon, Monday April 19, Room B)
Chair: Kitajewski, Jan & Monia, Brett

Phosphorylation/Signaling Monday 19 April 1999
13:30-13:50 * Kitajewski, Jan, Assistant Professor of Pathology, Columbia University, New York, NY: "Wnt signaling and growth control" (20 min)
14:00-14:30 * Bennett, Frank, Vice President, Biology, ISIS Pharmaceuticals, Carlsbad Research Center, Carlsbad, CA: "Use of antisense oligonucleotides to functionalize TNFa signaling pathways" (30 min)"
14:40-15:10 * Monia, Brett, Director, Molecular Pharmacology, ISIS Pharmaceuticals, Carlsbad Research Center, Carlsbad, CA: Antisense approaches to study MAP kinase signaling" (30 min)
15: 20-15-40 * Huberman, Eliezer, Center for Mechanistic Biology, Argonne National Laboratory, Argonne, IL: A novel lineage-specific protein kinase crucial for myeloid maturation (20 min)

15:45-16:05 COFFEE

16:05-16:25 * Soderlin, Thomas, Professor, Vollum Institute, Oregon Health Sciences University: "The CaM-kinase Cascade: Role in Transcriptional Regulation"
16:30-16:50 * Zhou, Mingdong, Lab Head, Victor Chang Cardiac Research Institute, Darlinghurst, New South Wales, Australia: Neuregulin-isoform-specific signaling in heart development (20 min)
17:00-18:30

18:30 END OF SESSIONS

Confirmed Biotech Companies
Abgenix, Inc., Fremont, CA
ALG Company, Marlboro, MA
Althea Technologies Inc., San Diego, CA
Alza Corporation, Mountain View, CA
Arcturus Engineering, Inc.
AVI Biopharma, Corvallis, Oregon
Avigen, Inc., Alameda, CA
BioInvent Therapeutic AB
Biometics, Inc. Waltham, MA
Biovector Therapeutics, Labège, France
Canji Inc., San Diego, CA
Cell Therapy Research Foundation, Memphis, TN
Chiron Technologies Center for Gene Therapy, San Diego, CA
Clontech, Palo Alto, CA
Cortex Pharmaceuticals, Inc., Irvine, CA
Cytoclonal Pharmaceuticals, Inc. Dallas, TX
Desmos, Inc., San Diego, CA
Durect, Santa Clara, CA
Fibrogen, Inc., South San Francisco, CA
GeneMedicine, Woodlands, TX
Genetronics, Inc., San Diego, CA
Genome Systems, Inc., St. Louis, MO
Genteric, Inc., Alameda, CA
Genzyme Corporation, Framingham, MA
GERON Corporation, Menlo Park CA
HERON Bioventures LLC, Palo Alto, CA
Hoffmann-La Roche, Basel, Switzerland
Inex Pharmaceuticals Corp., Burnaby, B.C., Canada
ImaRx Pharmaceutical Corp., Tucson, Arizona
Incyte, Palo Alto, CA
INCYTE Microarray Systems, Fremont, CA
INHALE, San Carlos, CA
Informax, Inc. North Bethesda, MD
Introgen Therapeutics, Inc. Houston, TX
ISIS Pharmaceuticals, Carlsbad, CA
MAXIA Pharmaceuticals, Inc., San Diego, CA
Megabios Corp., Burlingame, CA
NewBiotics, Inc., San Diego, CA
Onyx Pharmaceuticals, Richmond, CA
Pangea Systems, Oakland, CA
PE Applied Biosystems, Foster City, CA
Regulon, Inc., Palo Alto, CA
RPR-Gencell, Hayward, CA
Selective Genetics, San Diego, CA
SEQUUS Pharmaceuticals, Menlo Park, CA
Somagenics Inc., Mountain View, CA
Systemix, Inc., Palo Alto, CA
Tropix PE Applied Biosystems Services
Vical, San Diego, CA

°